CDNA Latest Quarter's Earnings
| Announce Date | 05/09/2024 |
| EPS Normalized Actual | $-0.03 (Beat by $0.16) |
| EPS GAAP Actual | $-0.03 (Beat by $0.16) |
| Revenue Actual | $0.079416B |
| Revenue Surprise | Beat by $79.416M |
Upcoming Quarter's Earnings
| Announce Date | 06/30/2024 (Pre-Market) |
| EPS Normalized Estimate | $1.34259 |
| EPS GAAP Estimate | $1.34259 |
| Revenue Estimate | $0.140602B |
Annual EPS Estimate
| Fiscal Period Ending | EPS Estimate | Forward PE | Low | High | # of Analysts |
|---|---|---|---|---|---|
| Dec 2026 | -1.63 | -9.51 | -1.67009 | -1.59648 | 1 |
| Dec 2025 | -1.405 | -11.03 | -2.02 | -0.79 | 2 |
Quarterly EPS History
| Period | EPS | Beat / Miss | Revenue | YoY | Beat / Miss |
|---|---|---|---|---|---|
| FQ1 2022 (Mar 2022) | -0.37 | -0.37 | 0.079416B | 15.13% | 79.42M |
| FQ4 2021 (Dec 2021) | -0.31 | -0.31 | 0.07922B | 25.97% | 79.22M |
| FQ3 2021 (Sep 2021) | -0.23 | -0.23 | 0.075589B | 29.4% | 75.59M |
| FQ2 2021 (Jun 2021) | -0.04 | -0.04 | 0.074188B | 43.66% | 74.19M |
| FQ1 2021 (Mar 2021) | -0.01 | -0.01 | 0.0674B | 43.06% | 67.4M |
| FQ4 2020 (Dec 2020) | -0.07 | -0.07 | 0.058644B | 38.92% | 58.64M |
| FQ3 2020 (Sep 2020) | -0.06 | -0.06 | 0.053369B | 36.65% | 53.37M |
| FQ2 2020 (Jun 2020) | -0.15 | -0.15 | 0.041801B | 24.75% | 41.8M |
Quarterly Estimates Summary
FQ4 Announce Date
06/30/2024 (Pre-Market)
Consensus EPS Estimates
1.34259
Consensus Revenue Estimates
0.140602B
Consensus EPS Estimates
| Fiscal Period Ending | EPS Estimate | YoY Growth(%) | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2026 (Oct 2026) | -0.4 | -- | -0.4112 | -0.39296 | 0 |
| FQ3 2026 (Jul 2026) | -0.41 | -- | -0.42148 | -0.40279 | 0 |
| FQ2 2026 (Jun 2026) | -0.41 | -- | -0.41512 | -0.40329 | 0 |
| FQ1 2026 (Mar 2026) | -0.43 | -- | -0.43537 | -0.42296 | 1 |
| FQ4 2025 (Oct 2025) | -0.30262 | -- | -0.31109 | -0.2973 | 1 |
| FQ3 2025 (Jul 2025) | -0.334 | -- | -0.34335 | -0.32812 | 1 |
| FQ2 2025 (Jun 2025) | -0.33405 | -- | -0.33822 | -0.32858 | 1 |
| FQ1 2025 (Mar 2025) | -0.38457 | -- | -0.38938 | -0.37827 | 1 |
| FQ4 2024 (Oct 2024) | -0.35924 | -- | -0.35292 | -0.32658 | 3 |
| FQ3 2024 (Jul 2024) | -0.41914 | -- | -0.41177 | -0.3912 | 3 |
| FQ2 2024 (Jun 2024) | 1.34259 | -- | 1.65586 | 1.20833 | 4 |
Consensus Revenue Estimates
| Fiscal Period Ending | Revenue Estimate | YoY Growth(%) | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2026 (Oct 2026) | 0.08B | -- | 0.08B | 0.09B | 2 |
| FQ3 2026 (Jul 2026) | 0.08B | -- | 0.08B | 0.08B | 2 |
| FQ2 2026 (Jun 2026) | 0.07B | -- | 0.07B | 0.07B | 2 |
| FQ1 2026 (Mar 2026) | 0.07B | -- | 0.07B | 0.07B | 2 |
| FQ4 2025 (Oct 2025) | 0.07B | -- | 0.07B | 0.08B | 1 |
| FQ3 2025 (Jul 2025) | 0.07B | -- | 0.07B | 0.07B | 1 |
| FQ2 2025 (Jun 2025) | 0.07B | -- | 0.07B | 0.07B | 1 |
| FQ1 2025 (Mar 2025) | 0.07B | -- | 0.07B | 0.07B | 1 |
| FQ4 2024 (Oct 2024) | 0.07B | -- | 0.07B | 0.07B | 5 |
| FQ3 2024 (Jul 2024) | 0.07B | -- | 0.07B | 0.07B | 5 |
| FQ2 2024 (Jun 2024) | 0.14B | -- | 0.11B | 0.17B | 19 |
Quarterly Estimates Revisions
EPS # of Up Revisions
4
EPS # of Down Revisions
4
Revenue # of Up Revisions
6
Revenue # of Down Revisions
3
Consensus EPS Revision Trend
| Fiscal Period Ending | EPS Estimate | YoY Growth | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2021 (Dec 2021) | 0.41 | -12.52% | 0.39 | 0.48 | 20 |
| FQ1 2022 (Mar 2022) | 0.59 | 6.89% | 0.55 | 0.62 | 15 |
| FQ2 2022 (Jun 2022) | 0.70 | 2.62% | 0.61 | 0.74 | 15 |
| FQ3 2022 (Sep 2022) | 0.68 | 4.62% | 0.65 | 0.70 | 15 |
Consensus Revenue Revision Trend
| Fiscal Period Ending | EPS Estimate | YoY Growth | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2021 (Dec 2021) | 0.41 | -12.52% | 0.39 | 0.48 | 20 |
| FQ1 2022 (Mar 2022) | 0.59 | 6.89% | 0.55 | 0.62 | 15 |
| FQ2 2022 (Jun 2022) | 0.70 | 2.62% | 0.61 | 0.74 | 15 |
| FQ3 2022 (Sep 2022) | 0.68 | 4.62% | 0.65 | 0.70 | 15 |
Earnings Surprise Summary
EPS # of Beats
0
EPS # of Misses
8
EPS # of in-lines
0
Revenue # of Beats
8
Revenue # of Misses
0
Revenue # of in-lines
0
Earnings Surprise (EPS) - Actual vs Consensus
| Earnings Date | EPS Estimate | EPS Actual | Surprise | Surprise % |
|---|---|---|---|---|
| FQ1 2022 (Mar 2022) | -0.37 | -0.37 | 100% | |
| FQ4 2021 (Dec 2021) | -0.31 | -0.31 | 100% | |
| FQ3 2021 (Sep 2021) | -0.23 | -0.23 | 100% | |
| FQ2 2021 (Jun 2021) | -0.04 | -0.04 | 100% | |
| FQ1 2021 (Mar 2021) | -0.01 | -0.01 | 100% | |
| FQ4 2020 (Dec 2020) | -0.07 | -0.07 | 100% | |
| FQ3 2020 (Sep 2020) | -0.06 | -0.06 | 100% | |
| FQ2 2020 (Jun 2020) | -0.15 | -0.15 | 100% |
Revenue Surprise - Actual vs Consensus
| Earnings Date | Revenue Estimate | Revenue Actual | Surprise | Surprise % |
|---|---|---|---|---|
| FQ1 2022 (Mar 2022) | $0B | $0.08B | $79.42M | 100% |
| FQ4 2021 (Dec 2021) | $0B | $0.08B | $79.22M | 100% |
| FQ3 2021 (Sep 2021) | $0B | $0.08B | $75.59M | 100% |
| FQ2 2021 (Jun 2021) | $0B | $0.07B | $74.19M | 100% |
| FQ1 2021 (Mar 2021) | $0B | $0.07B | $67.4M | 100% |
| FQ4 2020 (Dec 2020) | $0B | $0.06B | $58.64M | 100% |
| FQ3 2020 (Sep 2020) | $0B | $0.05B | $53.37M | 100% |
| FQ2 2020 (Jun 2020) | $0B | $0.04B | $41.8M | 100% |
CDNA Ratings Summary
CDNA Quant Ranking
